Inhibiting ALDH3B1: A Promising Drug Target for Cancer and Neurodegenerative Disorders

Target Name: ALDH3B1

NCBI ID: G221

ALDH3B1

Inhibiting ALDH3B1: A Promising Drug Target for Cancer and Neurodegenerative Disorders

ALDH3B1 (ALDH4), a member of the Aldehyde Reductase family 3 (ALDH3), is a protein that plays a crucial role in cellular metabolism. Specifically, it is involved in the metabolism of volatile organic compounds (VOCs), such as ethanol and acetaldehyde, which are byproducts of cellular metabolism and can be toxic to the cell.

The study of ALDH3B1 and its potential as a drug target has been a topic of interest in recent years due to its involvement in various cellular processes, including the detoxification of harmful substances and the regulation of cellular signaling pathways.

ALDH3B1 functions as a key enzyme in the metabolism of VOCs, which are naturally occurring compounds that are produced by cellular metabolism. VOCs are often generated as byproducts of cellular processes, such as cellular respiration, glycolysis, and the citric acid cycle. These compounds can be toxic to the cell and can cause various cellular stressures, including the death of cells under high concentrations.

ALDH3B1 helps to reduce the toxicity of VOCs by catalyzing the conversion of these compounds to less toxic byproducts. This process involves the formation of a carbeneside, which is then converted to a more neutral compound by another enzyme called ALDH3B2.

The study of ALDH3B1 and its potential as a drug target has led to the development of various compounds that can inhibit the activity of this enzyme. These compounds have been shown to have a variety of therapeutic potential, including the potential to treat various diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising compounds that has been shown to inhibit the activity of ALDH3B1 is called ALDH4 inhibitor BHV-350. This compound was developed by researchers at the University of California, San Diego and has been shown to have a variety of therapeutic potential, including the potential to treat various cancers.

In addition to its potential as a cancer therapeutic, ALDH4 inhibitor BHV-350 has also been shown to have potential in treating other diseases, such as neurodegenerative disorders and autoimmune disorders.

While the development of ALDH4 inhibitors is an promising area of research, there are also concerns about the potential side effects of these compounds. For example, some studies have suggested that ALDH4 inhibitors may have negative impacts on the cardiovascular system and may increase the risk of certain diseases.

Overall, the study of ALDH3B1 and its potential as a drug target is an exciting and rapidly developing area of research. While further research is needed to fully understand the potential of these compounds, the study of ALDH3B1 and its role in cellular metabolism has the potential to lead to the development of new and effective therapies for a variety of diseases.

Protein Name: Aldehyde Dehydrogenase 3 Family Member B1

Functions: Oxidizes medium and long chain saturated and unsaturated aldehydes (PubMed:17382292, PubMed:23721920). Metabolizes also benzaldehyde (PubMed:17382292). Low activity towards acetaldehyde and 3,4-dihydroxyphenylacetaldehyde (PubMed:17382292, PubMed:23721920). May not metabolize short chain aldehydes. Can use both NADP(+) and NAD(+) as electron acceptor (PubMed:17382292). May have a protective role against the cytotoxicity induced by lipid peroxidation (PubMed:17382292)

The "ALDH3B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH3B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets